cholecalciferol and Addison-Disease

On the basis of the immunomodulatory actions of vitamin D (VD), we investigated the effects of high-dose VD therapy over a 3 mo period on the immune response in patients with Addison's disease (AD).. This randomized, controlled, crossover trial included 13 patients with AD who received either cholecalciferol (4000 IU/d) for 3 mo followed by 3 mo placebo oil or the sequential alternative placebo followed by verum. Glucocorticoid replacement doses remained stable. The primary outcome measures were changes in 25-hydroxyvitamin D3 (25(OH)D. Three months of treatment with cholecalciferol achieved sufficient 25(OH)D

Topics: Addison Disease; Adult; Calcifediol; Cholecalciferol; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Monocytes; Pilot Projects; T-Lymphocytes, Regulatory; Treatment Outcome; Vitamin D Deficiency; Vitamins